Cargando…

Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages

The HIV-1 accessory proteins Vif, Vpu, and Nef can promote infection by overcoming the inhibitory effects of the host cell restriction factors APOBEC3G, Tetherin, and SERINC5, respectively. However, how the HIV-1 accessory protein Vpr enhances infection in macrophages but not in CD4(+) T cells remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Li, Wang, Shumei, Xu, Meng, He, Yang, Zhang, Xiaowei, Xiong, Ying, Sun, Hong, Ding, Haibo, Geng, Wenqing, Shang, Hong, Liang, Guoxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211709/
https://www.ncbi.nlm.nih.gov/pubmed/34140527
http://dx.doi.org/10.1038/s41467-021-24087-8
_version_ 1783709523636125696
author Zhao, Li
Wang, Shumei
Xu, Meng
He, Yang
Zhang, Xiaowei
Xiong, Ying
Sun, Hong
Ding, Haibo
Geng, Wenqing
Shang, Hong
Liang, Guoxin
author_facet Zhao, Li
Wang, Shumei
Xu, Meng
He, Yang
Zhang, Xiaowei
Xiong, Ying
Sun, Hong
Ding, Haibo
Geng, Wenqing
Shang, Hong
Liang, Guoxin
author_sort Zhao, Li
collection PubMed
description The HIV-1 accessory proteins Vif, Vpu, and Nef can promote infection by overcoming the inhibitory effects of the host cell restriction factors APOBEC3G, Tetherin, and SERINC5, respectively. However, how the HIV-1 accessory protein Vpr enhances infection in macrophages but not in CD4(+) T cells remains elusive. Here, we report that Vpr counteracts lysosomal-associated transmembrane protein 5 (LAPTM5), a potent inhibitor of HIV-1 particle infectivity, to enhance HIV-1 infection in macrophages. LAPTM5 transports HIV-1 envelope glycoproteins to lysosomes for degradation, thereby inhibiting virion infectivity. Vpr counteracts the restrictive effects of LAPTM5 by triggering its degradation via DCAF1. In the absence of Vpr, the silencing of LAPTM5 precisely phenocopied the effect of Vpr on HIV-1 infection. In contrast, Vpr did not enhance HIV-1 infection in the absence of LAPTM5. Moreover, LAPTM5 was highly expressed in macrophages but not in CD4(+) T lymphocytes. Re-expressing LAPTM5 reconstituted the Vpr-dependent promotion of HIV-1 infection in primary CD4(+) T cells, as observed in macrophages. Herein, we demonstrate the molecular mechanism used by Vpr to overcome LAPTM5 restriction in macrophages, providing a potential strategy for anti-HIV/AIDS therapeutics.
format Online
Article
Text
id pubmed-8211709
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82117092021-07-01 Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages Zhao, Li Wang, Shumei Xu, Meng He, Yang Zhang, Xiaowei Xiong, Ying Sun, Hong Ding, Haibo Geng, Wenqing Shang, Hong Liang, Guoxin Nat Commun Article The HIV-1 accessory proteins Vif, Vpu, and Nef can promote infection by overcoming the inhibitory effects of the host cell restriction factors APOBEC3G, Tetherin, and SERINC5, respectively. However, how the HIV-1 accessory protein Vpr enhances infection in macrophages but not in CD4(+) T cells remains elusive. Here, we report that Vpr counteracts lysosomal-associated transmembrane protein 5 (LAPTM5), a potent inhibitor of HIV-1 particle infectivity, to enhance HIV-1 infection in macrophages. LAPTM5 transports HIV-1 envelope glycoproteins to lysosomes for degradation, thereby inhibiting virion infectivity. Vpr counteracts the restrictive effects of LAPTM5 by triggering its degradation via DCAF1. In the absence of Vpr, the silencing of LAPTM5 precisely phenocopied the effect of Vpr on HIV-1 infection. In contrast, Vpr did not enhance HIV-1 infection in the absence of LAPTM5. Moreover, LAPTM5 was highly expressed in macrophages but not in CD4(+) T lymphocytes. Re-expressing LAPTM5 reconstituted the Vpr-dependent promotion of HIV-1 infection in primary CD4(+) T cells, as observed in macrophages. Herein, we demonstrate the molecular mechanism used by Vpr to overcome LAPTM5 restriction in macrophages, providing a potential strategy for anti-HIV/AIDS therapeutics. Nature Publishing Group UK 2021-06-17 /pmc/articles/PMC8211709/ /pubmed/34140527 http://dx.doi.org/10.1038/s41467-021-24087-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhao, Li
Wang, Shumei
Xu, Meng
He, Yang
Zhang, Xiaowei
Xiong, Ying
Sun, Hong
Ding, Haibo
Geng, Wenqing
Shang, Hong
Liang, Guoxin
Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages
title Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages
title_full Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages
title_fullStr Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages
title_full_unstemmed Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages
title_short Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages
title_sort vpr counteracts the restriction of laptm5 to promote hiv-1 infection in macrophages
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211709/
https://www.ncbi.nlm.nih.gov/pubmed/34140527
http://dx.doi.org/10.1038/s41467-021-24087-8
work_keys_str_mv AT zhaoli vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages
AT wangshumei vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages
AT xumeng vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages
AT heyang vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages
AT zhangxiaowei vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages
AT xiongying vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages
AT sunhong vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages
AT dinghaibo vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages
AT gengwenqing vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages
AT shanghong vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages
AT liangguoxin vprcounteractstherestrictionoflaptm5topromotehiv1infectioninmacrophages